xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT06029478</url>
    </required_header>
    <id_info>
      <org_study_id>84518615</org_study_id>
      <nct_id>NCT06029478</nct_id>
    </id_info>
    <brief_title>Understanding Engagement Trends in Chondrosarcoma Clinical Trials</brief_title>
    <official_title>Understanding Engagement Trends in Chondrosarcoma Clinical Trials: Investigating Participation Patterns Among Chondrosarcoma Patients</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>Power Life Sciences Inc.</agency>
        <agency_class>Industry</agency_class>
      </lead_sponsor>
    </sponsors>
    <source>Power Life Sciences Inc.</source>
    <oversight_info>
      <is_fda_regulated_drug>No</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        Taking part in medical research usually favors a particular demographic group. But there is&#xD;
        limited research available to explain what trial attributes affect the completion of these&#xD;
        specific demographic groups.&#xD;
  &#xD;
        This study will admit a wide range of data on the clinical trial experience of chondrosarcoma&#xD;
        patients to determine which factors prevail in limiting a patient's ability to join or finish&#xD;
        a trial.&#xD;
  &#xD;
        It will also try to analyze data from the perspective of different demographic groups to&#xD;
        check for recurring trends which might yield insights for the sake of future chondrosarcoma&#xD;
        patients.&#xD;
      </textblock>
    </brief_summary>
    <overall_status>Not yet recruiting</overall_status>
    <start_date type="Anticipated">October 2024</start_date>
    <completion_date type="Anticipated">October 2026</completion_date>
    <primary_completion_date type="Anticipated">October 2025</primary_completion_date>
    <study_type>Observational</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <observational_model>Case-Crossover</observational_model>
      <time_perspective>Prospective</time_perspective>
    </study_design_info>
    <primary_outcome>
      <measure>Number of chondrosarcoma patients who decide to enroll in a clinical trial</measure>
      <time_frame>3 months</time_frame>
    </primary_outcome>
    <primary_outcome>
      <measure>Rate of chondrosarcoma patients who remain in clinical trial to trial completion</measure>
      <time_frame>12 months</time_frame>
    </primary_outcome>
    <enrollment type="Anticipated">500</enrollment>
    <condition>Chondrosarcoma</condition>
    <eligibility>
      <study_pop>
        <textblock>
          Patients with chondrosarcoma who are actively considering enrolling in a clinical trial for&#xD;
          said condition, but have not yet completed enrollment and randomization.&#xD;
        </textblock>
      </study_pop>
      <sampling_method>Probability Sample</sampling_method>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
            -  Aged ≥ 18 years old&#xD;
  &#xD;
            -  Able to comprehend the investigational nature of the protocol and provide informed&#xD;
               consent&#xD;
  &#xD;
            -  Diagnosis of chondrosarcoma&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
            -  No diagnosis of chondrosarcoma confirmed&#xD;
  &#xD;
            -  Inability to perform regular electronic reporting&#xD;
  &#xD;
            -  Patient does not understand, sign, and return consent form&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>18 Years</minimum_age>
      <maximum_age>N/A</maximum_age>
      <healthy_volunteers>No</healthy_volunteers>
    </eligibility>
    <overall_official>
      <last_name>Michael B Gill</last_name>
      <role>Study Director</role>
      <affiliation>Power Life Sciences Inc.</affiliation>
    </overall_official>
    <overall_contact>
      <last_name>Michael B Gill</last_name>
      <phone>415-900-4227</phone>
      <email>bask@withpower.com</email>
    </overall_contact>
    <location>
      <facility>
        <name>Power Life Sciences</name>
        <address>
          <city>San Francisco</city>
          <state>California</state>
          <zip>94107</zip>
          <country>United States</country>
        </address>
      </facility>
      <contact>
        <last_name>Michael B Gill</last_name>
        <phone>415-900-4227</phone>
        <email>https://www.withpower.com/contact-us@withpower.com</email>
      </contact>
    </location>
    <location_countries>
      <country>United States</country>
    </location_countries>
    <reference>
      <citation>Speetjens FM, de Jong Y, Gelderblom H, Bovee JV. Molecular oncogenesis of chondrosarcoma: impact for targeted treatment. Curr Opin Oncol. 2016 Jul;28(4):314-22. doi: 10.1097/CCO.0000000000000300.</citation>
      <PMID>27166664</PMID>
    </reference>
    <reference>
      <citation>Beena D, Kattoor J, Mathews A, P Nair S, M V, T P, N G. Mesenchymal Chondrosarcoma-A Retrospective study. Gulf J Oncolog. 2021 Jan;1(35):54-58.</citation>
      <PMID>33716213</PMID>
    </reference>
    <reference>
      <citation>Thompson LD, Gannon FH. Chondrosarcoma of the larynx: a clinicopathologic study of 111 cases with a review of the literature. Am J Surg Pathol. 2002 Jul;26(7):836-51. doi: 10.1097/00000478-200207000-00002.</citation>
      <PMID>12131151</PMID>
    </reference>
    <verification_date>September 2023</verification_date>
    <study_first_submitted>September 1, 2023</study_first_submitted>
    <study_first_submitted_qc>September 1, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">September 8, 2023</study_first_posted>
    <last_update_submitted>September 1, 2023</last_update_submitted>
    <last_update_submitted_qc>September 1, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">September 8, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Sponsor</responsible_party_type>
    </responsible_party>
    <keyword>chondrosarcoma</keyword>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Chondrosarcoma</mesh_term>
    </condition_browse>
    <patient_data>
      <sharing_ipd>Undecided</sharing_ipd>
    </patient_data>
    <provided_document_section>
      <provided_document>
        <document_type>Informed Consent Form</document_type>
        <document_has_protocol>No</document_has_protocol>
        <document_has_icf>Yes</document_has_icf>
        <document_has_sap>No</document_has_sap>
        <document_date>September 1, 2023</document_date>
        <document_url>https://ClinicalTrials.gov/ProvidedDocs/78/NCT06029478/ICF_000.pdf</document_url>
      </provided_document>
    </provided_document_section>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT06029478
  org study id: 84518615
  nct id: NCT06029478
  lead sponsor: 
  is fda regulated drug: No
  is fda regulated device: No
  Taking part in medical research usually favors a particular demographic group. But there is
        limited research available to explain what trial attributes affect the completion of these
        specific demographic groups.
  
        This study will admit a wide range of data on the clinical trial experience of chondrosarcoma
        patients to determine which factors prevail in limiting a patient's ability to join or finish
        a trial.
  
        It will also try to analyze data from the perspective of different demographic groups to
        check for recurring trends which might yield insights for the sake of future chondrosarcoma
        patients.
  observational model: Case-Crossover
  time perspective: Prospective
  measure: Number of chondrosarcoma patients who decide to enroll in a clinical trial
  time frame: 3 months
  measure: Rate of chondrosarcoma patients who remain in clinical trial to trial completion
  time frame: 12 months
  study pop: 
  sampling method: Probability Sample
  criteria: 
  gender: All
  minimum age: 18 Years
  maximum age: N/A
  healthy volunteers: No
  last name: Michael B Gill
  role: Study Director
  affiliation: Power Life Sciences Inc.
  last name: Michael B Gill
  phone: 415-900-4227
  email: bask@withpower.com
  facility: 
  contact: 
  country: United States
  citation: Speetjens FM, de Jong Y, Gelderblom H, Bovee JV. Molecular oncogenesis of chondrosarcoma: impact for targeted treatment. Curr Opin Oncol. 2016 Jul;28(4):314-22. doi: 10.1097/CCO.0000000000000300.
  PMID: 27166664
  citation: Beena D, Kattoor J, Mathews A, P Nair S, M V, T P, N G. Mesenchymal Chondrosarcoma-A Retrospective study. Gulf J Oncolog. 2021 Jan;1(35):54-58.
  PMID: 33716213
  citation: Thompson LD, Gannon FH. Chondrosarcoma of the larynx: a clinicopathologic study of 111 cases with a review of the literature. Am J Surg Pathol. 2002 Jul;26(7):836-51. doi: 10.1097/00000478-200207000-00002.
  PMID: 12131151
  responsible party type: Sponsor
  mesh term: Chondrosarcoma
  sharing ipd: Undecided
  provided document: 